

The Nomination Committee's proposal for Board of Directors to the 2026 Annual General Meeting

The Nomination Committee of Bactiguard Holding AB (the "Company") today informs about the proposal regarding the composition of the Board of Directors for the Annual General Meeting on 19 May 2026.

The Nomination Committee proposes re-election of Thomas von Koch, Dr Richard Kuntz, Professor Anna Martling, Magdalena Persson and Jan Ståhlberg as Board Members. Thomas von Koch is proposed to be re-elected as the Chairman of the Board of Directors.

The Nomination Committee's other proposals will be made public in the notice convening the Annual General Meeting to be held on 19 May 2026.

The Nomination Committee for the 2026 Annual General Meeting consists of Helena Borglund (Chairman of the Nomination Committee), appointed by TomBact AB (a company controlled by Thomas von Koch), Malin af Petersens, appointed by GIDL Invest AB (a company controlled Christian Kinch), Mats J Andersson, appointed by Nordea Fonder AB, Jannis Kitsakis, appointed by the Fourth AP Fund, and Jan Ståhlberg, appointed by Jan Ståhlberg.

For further information, please contact:

Patrick Bach, CFO +46 761 295 911

About Bactiguard

Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas where infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access.

Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices. The company also has a portfolio of wound management products. Bactiguard's infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine. Bactiguard is headquartered in Stockholm and is listed on Nasdaq Stockholm and is included in the Small-Cap segment.

Read more about Bactiguard: www.bactiguard.com

Follow Bactiguard on [LinkedIn](#)